Charles River Laboratories International (CRL) Long-Term Investments (2010 - 2026)

Charles River Laboratories International has reported Long-Term Investments for 10 years, with the latest figure at $206.5 million in Q2 2026.

• On a quarterly basis, Long-Term Investments fell 4.44% year-over-year to $206.5 million in Q2 2026; TTM through Jun 2026 was $206.5 million, a 4.44% decrease from a year earlier, with the FY2025 full-year figure at $207.0 million, down 5.21% from the prior year.
• Long-Term Investments was $206.5 million for Q2 2026 at Charles River Laboratories International, down from $209.7 million in the prior quarter.
• The five-year high for Long-Term Investments was $311.6 million in Q4 2022, with the low at $60.6 million in Q1 2022.
• Average Long-Term Investments over 5 years is $222.2 million, with a median of $217.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments jumped 384.99% in 2023, then retreated 22.79% in 2024.
• Over 5 years, Long-Term Investments stood at $311.6 million in 2022, then declined by 21.76% to $243.8 million in 2023, then declined by 10.44% to $218.4 million in 2024, then fell by 5.21% to $207.0 million in 2025, then slipped by 0.24% to $206.5 million in 2026.
• The last three Long-Term Investments figures came in at $206.5 million (Q2 2026), $209.7 million (Q1 2026), and $207.0 million (Q4 2025), per Business Quant data.